参考文献アーカイブ：NOD/ShiJic-scidJcl

2017

• Takeda K, Mori S, Kodama T.
  Study of fluid dynamics reveals direct communications between lymphatic vessels and venous blood vessels at lymph nodes of mice
  J Immunol Methods. 2017 Jun;445:1-9. doi: 10.1016/j.jim.2017.02.008. Epub 2017 Feb 22.PMID: 28237707

2018

• Umehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad TM, Willey J, Kaito H, Shiraishi N, Nakashima D, Akinaga S, Ueno NT.
  Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole
  Ther Adv Med Oncol. 2018 Jul 30;10:1758835918786858. doi: 10.1177/1758835918786858. PMCID: PMC6066809

• Okubo T, Nagoshi N, Kohyama J, Tsuji O, Shinozaki M, Shibata S, Kase Y, Matsumoto M, Nakamura M, Okano H.
  Treatment with a Gamma-Secretase Inhibitor Promotes Functional Recovery in Human iPSC- Derived Transplants for Chronic Spinal Cord Injury
  Stem Cell Reports. 2018 Nov 29;11(6):1416-1432. doi: 10.1016/j.stemcr.2018.10.022. PMCID: PMC6294244

• Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S.
  Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits
  Oncotarget. 2018 Jan 11;9(11):9975-9991. doi: 10.18632/oncotarget.24160. PMCID: PMC5839415

2019

• Asakawa M, Itoh M, Suganami T, Sakai T, Kanai S, Shirakawa I, Yuan X, Hatayama T, Shimada S, Akiyama Y, Fujiu K, Inagaki Y, Manabe I, Yamaoka S, Yamada T, Tanaka S, Ogawa Y.
  Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis
  Sci Rep. 2019 Dec 20;9(1):19601. doi: 10.1038/s41598-019-56039-0. PMCID: PMC6925281

• Ito E, Miyagawa S, Takeda M, Kawamura A, Harada A, Iseoka H, Yajima S, Sougawa N, Mochizuki-Oda N, Yasuda S, Sato Y, Sawa Y.
  Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application
  Sci Rep. 2019 Feb 13;9(1):1881. doi: 10.1038/s41598-018-38325-5. PMCID: PMC6374479

2020

• Haramoto Y, Onuma Y, Mawaribuchi S, Nakajima Y, Aiki Y, Higuchi K, Shimizu M, Tateno H, Hirabayashi J, Ito Y.
  A technique for removing tumourigenic pluripotent stem cells using rBC2LCN lectin
  Regen Ther. 2020 May 19;14:306-314. doi: 10.1016/j.reth.2020.03.017. PMCID: PMC7240284

2022

• Nakagawa M, Yamaguchi M, Endo M, Machida Y, Hattori A, Tanzawa F, Tsutsumi S, Kitabayashi I, Kawai A, Nakatani F.
  Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.
  J Bone Oncol. 2022 Apr 16;34:100430. doi: 10.1016/j.jbo.2022.100430. eCollection 2022 Jun.PMID: 35493690

• Komatsu SI, Kayukawa Y, Miyazaki Y, Kaneko A, Ikegami H, Ishiguro T, Nakamura M, Frings W, Ono N, Sakata K, Fujii T, Kishishita S, Kitazawa T, Endo M, Sano Y.
  Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial
  Sci Rep. 2022 Jul 19;12(1):12312. doi: 10.1038/s41598-022-16564-x. PMCID: PMC9296674

2023

• Sihombing AM, Murata S, Shimoji M, Miyake T, Takebayashi K, Kodama H, Tokuda A, Kojima M, Ueki T, Kitamura N, Kitamura M, Mekata E, Tani M.
  CD44-positive Cancer Stem-like Cells as a Potential Source of Peritoneal Metastasis After Surgery.
  Anticancer Res. 2023 Jun;43(6):2491-2500. doi: 10.21873/anticanres.16416.PMID: 37247920

• Hsu CY, Yanagi T, Maeda T, Nishihara H, Miyamoto K, Kitamura S, Tokuchi K, Ujiie H.
  Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft
  Sci Rep. 2023 May 27;13(1):8650. doi: 10.1038/s41598-023-35811-3. PMCID: PMC10224945

• Osaki T, Sunden Y, Warita K, Okamoto Y.
  Comparison of Characterization in Two-Dimensional and Three-Dimensional Canine Mammary Gland Tumor Cell Models
  Yonago Acta Med. 2023 Feb 20;66(1):7-18. doi: 10.33160/yam.2023.02.002. PMCID: PMC9937961

2024

• Nakamura K, Takahashi K, Sakaguchi I, Satoh T, Zhang L, Yanai H, Tsukumo Y.
  A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models †
  Int J Mol Sci. 2024 Dec 19;25(24):13627. doi: 10.3390/ijms252413627. PMCID: PMC11679542

• Hsu CY, Yanagi T, Maeda T, Nishihara H, Funakoshi T, Miyamoto K, Iwamoto R, Takahashi K, Ujiie H.
  Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism
  Br J Cancer. 2024 Jul 10;131(5):944-953. doi: 10.1038/s41416-024-02788-3. PMCID: PMC11369254

2026

• Osaki T, Kadohata T, Yasunaga M, Hishikawa S, Sunden Y, Takahashi K.
  Establishment and Characterization of Canine Malignant Mesothelioma Cells
  Yonago Acta Med. 2026 May 4;69(2):195-203. doi: 10.33160/yam.2026.05.007. PMCID: PMC13198971